DELTA (Detecting and Predicting Atrial Fibrillation in Post-Stroke Patients)

Recruiting Observational Study
Stroke, Ischemic
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
55 and older
Sex
Any
Study type
Observational
Participants needed
500 (estimated)
Sponsor
Emory University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Atrial Fibrillation (AF) is an abnormal heart rhythm. Because AF is often asymptomatic, it often remains undiagnosed in the early stages. Anticoagulant therapy greatly reduces the risks of stroke in patients diagnosed with AF. However, diagnosis of AF requires long-term ambulatory monitoring procedures that are burdensome and/or expensive. Smart devices (such as Apple or Fitbit) use light sensors…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adults 55 years of age or older. * Post-discharge with diagnostic of index ischemic stroke with uncertain cause. * Subject must be treated at the Emory Stroke Clinic for follow-up treatment. * Subject must be prescribed a clinical extended cardiac monitoring. * Subject or thei…
Contacts

Xiao Hu, PhD

404-712-8520

xhu40@emory.edu

CONTACT

Corey Williams

404-251-4060

corey.williams2@emory.edu

CONTACT